AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study.(1)

Neutralisation titres for Omicron were boosted following a third dose with Vaxzevria compared to titres after a second dose.(1)